This may explain why obese patients with type 2 diabetes (T2D) have decreased hepatic AQP9, compatible with a compensatory mechanism aimed at reducing the glycerol entry into hepatocytes and further enhancing the development of hyperglycemia (Figure 2) (10, 19). The gene discussed is AQP9; the disease is type 2 diabetes mellitus.